Loss of ACVRIB Leads to Increased Squamous Cell Carcinoma Aggressiveness Through Alterations in Cell-cell and Cell-matrix Adhesion Proteins
Overview
Affiliations
Squamous cell carcinomas of the head and neck (HNSCC) and esophagus (ESCC) pose a global public health issue due to high mortality rates. Unfortunately, little progress has been made in improving patient outcomes. This is partially a result of a lack of understanding the mechanisms that drive SCC progression. Recently, Activin A signaling has been implicated in a number of cancers, yet the role of this pathway in SCC remains poorly understood. We have previously discovered that the Activin A ligand acts as a tumor suppressor when epithelial Activin receptor type IB (ACVRIB) is intact; however, this effect is lost upon ACVRIB downregulation. In the present study, we investigated the function of ACVRIB in the regulation of SCC. Using CRISPR/Cas9-mediated ACVRIB-knockout and knockdown using siRNA, we found an increased capacity to proliferate, migrate, and invade upon ACRIB loss, as ACVRIB-KO cells exhibited an altered cytoskeleton and aberrant expression of E-cadherin and integrins. Based on chemical inhibitor studies, our data suggests that these effects are mediated through ACVRIB-independent signaling via downstream activation of Smad1/5/8 and MEK/ERK. Overall, we present a novel mechanism of SCC progression upon ACVRIB loss by showing that Activin A can transduce a signal in the absence of ACVRIB.
The Role of SOX2 and SOX9 in Radioresistance and Tumor Recurrence.
Barbosa S, Laureano N, Wijaya Hadiwikarta W, Visioli F, Bonrouhi M, Pajdzik K Cancers (Basel). 2024; 16(2).
PMID: 38275880 PMC: 10814462. DOI: 10.3390/cancers16020439.
Potential Roles of Activin in Head and Neck Squamous Cell Carcinoma Progression and Mortality.
Buryska S, Patel K, Wuertz B, Gaffney P, Ondrey F Anticancer Res. 2023; 43(12):5299-5310.
PMID: 38030164 PMC: 11285815. DOI: 10.21873/anticanres.16733.
Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma.
Pinjusic K, Dubey O, Egorova O, Nassiri S, Meylan E, Faget J J Immunother Cancer. 2022; 10(5).
PMID: 35580932 PMC: 9125758. DOI: 10.1136/jitc-2022-004533.